Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors
SAN DIEGO , Dec. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Manmeet S. Soni as a non-executive director. Mr. Soni is a highly accomplished senior finance executive with extensive experience in the life sciences industry.
View HTML
Toggle Summary Arena Pharmaceuticals Expands Senior Management Team to Support Commercialization and Medical Affairs
SAN DIEGO , Nov. 26, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointments of Robert Lisicki as Executive Vice President and Chief Commercial Officer, and Paul K. Audhya , MD, MBA, as Senior Vice President, Medical Affairs. Mr.
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Calif. , Nov. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference – Presenting on Wednesday, November 28 , at 4:15PM EST in
View HTML
Toggle Summary Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
- Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments - United Therapeutics will receive exclusive, worldwide rights to ralinepag - a potential best-in-class agent for the treatment of pulmonary arterial hypertension
View HTML
Toggle Summary Arena Pharmaceuticals Presented Preclinical Data for APD418 in Development for Treatment of Decompensated Heart Failure at American Heart Association Scientific Sessions
SAN DIEGO , Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2018 Financial Results
- Ralinepag open-label extension data demonstrated durable, long-term improvements in both PVR and 6MWD - Olorinab positive Phase 2a data for the treatment of pain associated with Crohn's disease; all patients with evaluable data at week 8 exhibited a pre-defined clinical improvement SAN DIEGO ,
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7
SAN DIEGO , Oct. 31, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its third quarter 2018 financial results and provide a corporate update on Wednesday, November 7, 2018 , after the close of the U.S. financial markets.
View HTML
Toggle Summary Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting
SAN DIEGO , Oct. 8, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a next-generation, oral, S1P receptor modulator with optimized activity being evaluated in
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension
- Ralinepag demonstrated durable, long-term improvements in both PVR and 6MWD - Favorable long-term tolerability profile demonstrated SAN DIEGO , Oct. 2, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from a planned interim analysis of the ongoing
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease
- Olorinab demonstrated a statistically significant improvement in abdominal pain over 8 weeks of treatment - All patients with evaluable data at week 8 exhibited a pre-defined clinical response of ≥30% change from baseline in AAPS - Treatment effects were demonstrated early and were consistent
View HTML